$ABXBullishMed

Abacus Global Management takes minority stake in Manning & Napier in longevity-focused alliance

Abacus Global Management (NYSE:ABX) said it formed a strategic alliance with Manning & Napier and completed a minority equity investment in the firm. The partnership covers lead/referral generation, product development and distribution, and joint client solutions, using Abacus’s LifeARC longevity and actuarial platform. Manning & Napier plans to integrate LifeARC into its advisory offering and may offer Abacus Asset Group products, including ETFs and longevity funds.

8/10
8/10
Med
Bullish
deal announcement published pre-market/early session (2026-05-29)
Growth/partnership positive; investors may re-rate longevity/wealth-tech distribution optionality.

Deal expands distribution of Abacus’s LifeARC and creates bidirectional lead/referral flows with a wealth manager.

Abacus Global Management closed a minority investment and alliance with Manning & Napier to scale its LifeARC longevity platform into wealth advisory.

Modest positive bias; likely limited near-term earnings impact but supportive for growth narrative.

Background

Abacus is positioning its LifeARC actuarial/longgevity data platform for integration into wealth advisory offerings, while Manning & Napier expands product distribution via Abacus’s investment solutions.

Why it matters

If Manning & Napier meaningfully integrates LifeARC and routes leads, Abacus could see improved customer acquisition and product uptake; however, the article provides no financial impact or timeline.

Market relevance

Strategic alliance plus minority investment is a concrete distribution/partnership catalyst for ABX, centered on integrating LifeARC into wealth advisory and enabling referral flows.

Market effects

Highlights increasing integration of longevity/actuarial data into wealth advisory and life-insurance planning workflows.

Primarily US wealth-management distribution; no explicit regional expansion details.

Longevity-data monetization model could be read across to other advisory platforms, but no global scope stated.

Alternative perspectives

Without deal economics or adoption metrics, the minority stake and referrals may not translate into material near-term revenue.

Execution risk: advisors’ willingness to adopt LifeARC tools and integrate them into planning processes will determine whether lead/referral flows convert into assets or policies.

Key entities

  • Abacus Global Management

    NYSE-listed firm providing the LifeARC longevity data platform and making a minority equity investment.

  • Manning & Napier

    Wealth and asset management firm partnering to integrate LifeARC and exchange referrals.

  • LifeARC platform

    Abacus proprietary actuarial modeling and longevity data used to factor lifespan/health outlook into financial planning.

Related articles

$ABXLow

Abacus Global Management named to TIME's inaugural World's Growth Leaders list

Abacus Global Management (NYSE:ABX) was named to TIME’s inaugural “World’s Growth Leaders of 2026” list, created with Statista. The ranking selects the top 1,000 public companies worldwide based on revenue growth, market performance, and financial stability. TIME said thousands of companies were evaluated. Abacus said the recognition reflects its platform’s work in longevity-based financial solutions.

$TTEMedAI 8/10

Ceasefire Uncertainty Remains the Biggest Driver for Oil Markets

Iran is reviewing a new U.S. ceasefire proposal, with Mehr agency saying authorities are considering it, which has capped Brent upside around $95/bbl. Separately, Ukraine’s strikes on Russian refineries are reportedly boosting Russian crude export loadings; 2026 seaborne exports average 3.46m b/d. Reuters says Venezuela exports rose to 1.25m b/d in May.

$WBDMedAI 9/10

Stock Market Today, June 5: Warner Bros. Discovery Falls on Reports of State Antitrust Challenge to Paramount Deal

Warner Bros. Discovery shares (WBD) fell 2.81% to $26.24 on June 5, after reports that multiple U.S. states, led by California and New York, are preparing antitrust lawsuits to block Paramount Global’s planned acquisition by Paramount Skydance. The article says the deal still needs U.S. and European approval despite shareholder approval, with potential remedies like divestitures.

$RMDMedAI 8/10

ResMed (RMD) Acquires Noctrix Health to Expand Sleep Disorder Portfolio

The article is a promotional piece claiming AI could be worth $250 trillion by 2040, citing Elon Musk’s estimate of 10 billion humanoid robots priced at $20,000–$25,000. It also advertises a newsletter and alleges an “underdog” stock trading at about $3 has cut $100 million in waste and offers “400% upside,” but it provides no verifiable company details.